SPOTLIGHT: GSK signing new vaccine deals

Fresh from signing a deal to supply Switzerland and Singapore with enough avian flu vaccine to inoculate the country's entire population, GlaxoSmithKline is now in talks to sign similar deals with France and the U.K. The vaccine has not yet been approved, but the EMEA's stamp of approval is expected in a matter of weeks. Some concerns have been raised that the new vaccine may not be effective against any new strain of avian flu that may trigger a human pandemic. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.